Employing Effective Multidisciplinary Care to Reduce the Burden of Myelodysplastic Syndrome  : Episode 1

Opinion

Video

November 17, 2023

Myelodysplastic Syndrome (MDS) Overview

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

Now Viewing

EP: 1.Myelodysplastic Syndrome (MDS) Overview

EP: 2.Distinguishing Between Different MDS Subtypes

EP: 3.MDS-Related Complications Impacting Patient Quality of Life

EP: 4.Economic Implications of MDS Management

EP: 5.Examining Treatment Algorithms for MDS

EP: 6.Growth Factor and Stem Cell Transplant Candidacy in MDS

EP: 7.Novel Agents Contributing to Evolving MDS Therapy Strategies

EP: 8.Benefits of Oral Therapies In MDS Treatment Adherence

EP: 9.Adapting MDS Treatment Approach

EP: 10.Novel Therapy Impact on Patient Quality of Life

EP: 11.Multidisciplinary Care Driving Effective MDS Treatment

EP: 12.Payor Considerations In MDS Management

EP: 13.Navigating Insurance-Related Challenges Associated With MDS Treatment

EP: 14.Key Considerations Surrounding MDS Treatment

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

August 9th 2025

Zongertinib Granted Accelerated Approval in Nonsquamous NSCLC for HER2 TKD-Activating Mutations

Mary Caffrey Brooke McCormick

August 9th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

August 9th 2025

Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC

Julia Bonavitacola

August 9th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

Depiction of inflammation | Image Credit: picture-waterfall - stock.adobe.com

August 9th 2025

Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds

Brooke McCormick

August 9th 2025

US Health Care Disparities in Immunology Biologics Access: A Systematic Review

Grace C. Wright, MD, PhD Ginette A. Okoye, MD Adam C. Ehrlich, MD, MPH D. J. Lorimier, PharmD, MS Shahnaz Khan, MPH Alisha Krumbach, PharmD Catherine Copley-Merriman, MS, MBA Kateryna Onishchenko, PhD Osayi Ovbiosa, PhD Manish Mittal, PhD

Related Content

August 9th 2025

Zongertinib Granted Accelerated Approval in Nonsquamous NSCLC for HER2 TKD-Activating Mutations

Mary Caffrey Brooke McCormick

August 9th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 9th 2025

Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC

Julia Bonavitacola

August 9th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 9th 2025

Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds

Brooke McCormick

August 9th 2025

US Health Care Disparities in Immunology Biologics Access: A Systematic Review

Myelodysplastic Syndrome (MDS) Overview

EP: 1.Myelodysplastic Syndrome (MDS) Overview

EP: 2.Distinguishing Between Different MDS Subtypes

EP: 3.MDS-Related Complications Impacting Patient Quality of Life

EP: 4.Economic Implications of MDS Management

EP: 5.Examining Treatment Algorithms for MDS

EP: 6.Growth Factor and Stem Cell Transplant Candidacy in MDS

EP: 7.Novel Agents Contributing to Evolving MDS Therapy Strategies

EP: 8.Benefits of Oral Therapies In MDS Treatment Adherence

EP: 9.Adapting MDS Treatment Approach

EP: 10.Novel Therapy Impact on Patient Quality of Life

EP: 11.Multidisciplinary Care Driving Effective MDS Treatment

EP: 12.Payor Considerations In MDS Management

EP: 13.Navigating Insurance-Related Challenges Associated With MDS Treatment

EP: 14.Key Considerations Surrounding MDS Treatment

Newsletter